Blue water announces acquisition of entadfi®, an fda-approved benign prostatic hyperplasia asset

Acquisition transforms the company into a broader pharmaceutical company spanning multiple sectors company announces corporate name change to underscore broader focus company to host a conference call today, april 20 th , at 8:30am edt to discuss asset purchase and company transformation cincinnati, april 20, 2023 (globe newswire) --  blue water vaccines inc. (“bwv” or “blue water” or the “company”), today announced the signing of an asset purchase agreement (the “agreement”) with veru inc. (“veru”) for the purchase of entadfi®, an fda-approved treatment for benign prostatic hyperplasia (“bph”) that counteracts negative sexual side effects seen in men on alternative bph therapies. under this agreement, blue water will purchase entadfi® for a total consideration of $100 million, with $20 million upfront, paid in defined tranches through september 2024, and the possibility of an additional $80 million based on predetermined annual sales milestones.
BWV Ratings Summary
BWV Quant Ranking